Long-term effect of polyalkylimide gel injections on severity of facial lipoatrophy and quality of life of HIV-positive patients

Aesthetic Plastic Surgery

Volumn 32, Issue 6, 2008, Pages 873-878

  Karim, Refaat B ^a   De Lint, Cathelijne A ^a   Van Galen, Sebastiaan R ^a   Van Rozelaar, Leo ^b   Nieuwkerk, Pythia T ^c   Askarizadeh, Erfan ^a   Hage, J Joris ^d  

^a Onze Lieve Vrouwe Gasthuis ^*  (Netherlands)

^b Medisch Laser Centrum   (Netherlands)

^c ACADEMIC MEDICAL CENTER   (Netherlands)

^d ANTONI VAN LEEUWENHOEK HOSPITAL   (Netherlands)

Author keywords

HAART; HIV; Lipoatrophy; Lipodystrophy; Polyalkylimide gel; Quality of life

Indexed keywords

BIO ALCAMID; IMIDE; POLYALKYLIMIDE; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; FACE LIPOATROPHY; FEMALE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; LIPOATROPHY; LIPODYSTROPHY; MALE; PRIORITY JOURNAL; QUALITY OF LIFE; QUESTIONNAIRE; SELF REPORT;

ACRYLIC RESINS; ADULT; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; BIOCOMPATIBLE MATERIALS; COHORT STUDIES; COSMETIC TECHNIQUES; ESTHETICS; FACE; FEMALE; GELS; HIV-ASSOCIATED LIPODYSTROPHY SYNDROME; HUMANS; INJECTIONS, SUBCUTANEOUS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; QUALITY OF LIFE; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 55349098242     PISSN: 0364216X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00266-008-9189-8     Document Type: Article

References (30)

1. FJ Palella Jr KM Delaney AC Moorman MO Loveless J Fuhrer GA Satten DJ Aschman SD Holmberg 1998 Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators N Engl J Med 338 853 860
2. A Carr K Samaras S Burton M Law J Freund DJ Chisholm DA Cooper 1998 A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors AIDS 12 F51 F58
3. M Oette P Juretzko A Kroidl A Sagir M Wettstein J Siegrist D Häussinger 2002 Lipodystrophy syndrome and self-assessment of well-being and physical appearance in HIV-positive patients AIDS Patient Care STDS 16 413 417
4. S Duran M Saves B Spire V Cailleton A Sobel P Carrieri D Salmon JP Moatti C Leport APROCO Study Group 2001 Failure to maintain long-term adherence to highly active antiretroviral therapy: the role of lipodystrophy AIDS 15 2441 2444
5. A Ammassari A Antinori A Cozzi-Lepri MP Trotta G Nasti AL Ridolfo F Mazzotta AW Wu A d'Arminio Monforte M Galli AdICoNA Study Group. LipoICoNA Study Group 2002 Relationship between HAART adherence and adipose tissue alterations J Acquir Immune Defic Syndr 31 Suppl 3 S140 S144
6. H Hatano KD Miller CP Yoder JA Yanovski NG Sebring EC Jones RT Davey Jr 2000 Metabolic and anthropometric consequences of interruption of highly active antiretroviral therapy AIDS 14 1935 1942
7. A Lafeuillade N Clumeck J Mallolas H Jaeger JM Livrozet S Ferreira Mdo M Johnson A Cheret Z Antoun European Trizal team 2003 Comparison of metabolic abnormalities and clinical lipodystrophy 48 weeks after switching from HAART to Trizivir versus continued HAART: the Trizal study HIV Clin Trials 4 37 43
8. M John EJ McKinnon IR James DA Nolan SE Herrmann CB Moore AJ White SA Mallal 2003 Randomized, controlled, 48-week study of switching stavudine and/or protease inhibitors to combivir/abacavir to prevent or reverse lipoatrophy in HIV-infected patients J Acquir Immune Defic Syndr 33 29 33
9. D Jones 2005 HIV facial lipoatrophy: causes and treatment options Dermatol Surg 31 1519 1529
10. A Carr C Workman D Carey G Rogers A Martin D Baker H Wand M Law K Samaras S Emery DA Cooper Rosey investigators 2004 No effect of rosiglitazone for treatment of HIV-1 lipoatrophy: randomised, double-blind, placebo-controlled trial Lancet 363 429 438
11. P Koutkia B Canavan J Breu M Torriani J Kissko S Grinspoon 2004 Growth hormone-releasing hormone in HIV-infected men with lipodystrophy: a randomized controlled trial JAMA 292 210 218
12. M Talmor LA Hoffman GS LaTrenta 2002 Facial atrophy in HIV-related fat redistribution syndrome: anatomic evaluation and surgical reconstruction Ann Plast Surg 49 11 18
13. B Strauch T Baum N Robbins 2004 Treatment of human immunodeficiency virus-associated lipodystrophy with dermafat graft transfer to the malar area Plast Reconstr Surg 113 363 370 discussion 371-372
14. P Levan TH Nguyen F Lallemand L Mazetier M Mimoun W Rozenbaum PM Girard 2002 Correction of facial lipoatrophy in HIV-infected patients on highly active antiretroviral therapy by injection of autologous fatty tissue AIDS 16 1985 1987
15. GJ Moyle L Lysakova S Brown N Sibtain J Healy C Priest S Mandalia SE Barton 2004 A randomized open-label study of immediate versus delayed polylactic acid injections for the cosmetic management of facial lipoatrophy in persons with HIV infection HIV Med 5 82 87
16. RA Walther 2002 [Facial lipodystrophy in patients with HIV infections troublesome to treat] Lakartidningen 99 3826 3829
17. D Orentreich AS Leone 2004 A case of HIV-associated facial lipoatrophy treated with 1000-cs liquid injectable silicone Dermatol Surg 30 548 551
18. MA Valantin C Aubron-Olivier J Ghosn E Laglenne M Pauchard H Schoen R Bousquet P Katz D Costagliola C Katlama 2003 Polylactic acid implants (New-Fill) to correct facial lipoatrophy in HIV-infected patients: results of the open-label study VEGA AIDS 17 2471 2477
19. MG Onesti LF Renzi F Paoletti N Scuderi 2004 Use of polylactic acid in face lipodystrophy in HIV positive patients undergoing treatment with antiretroviral drugs (HAART) Acta Chir Plast 46 12 15
20. E Negrado C Higueras X Adell JC Martinez E Martinez J Puig CR Fumaz JA Muñoz-Moreno N Perez-Alvarez S Videla C Estany D Cinquegrana V Gonzalez-Mestre B Clotet 2006 Reconstructive treatment for antiviral-associated facial lipoatrophy: a prospective study comparing autologous fat and synthetic substances AIDS Patient Care STDS 20 829 837
21. SL Comite JF Liu S Balasubramanian MA Christian 2004 Treatment of HIV-associated facial lipoatrophy with Radiance FN (Radiesse) Dermatol Online J 10 2
22. C Protopapa G Sito D Caporale N Cammarota 2003 Bio-Alcamid in drug-induced lipodystrophy J Cosmet Laser Ther 5 226 230
23. MR Loutfy JM Raboud T Antoniou C Kovacs S Shen R Halpenny D Ellenor D Ezekiel A Zhao F Beninger 2007 Immediate versus delayed polyalkylimide gel injections to correct facial lipoatrophy in HIV-positive patients AIDS 21 1147 1155
24. RB Karim JJ Hage L van Rozelaar CA Lange J Raaijmakers 2006 Complications of polyalkylimide 4% injections (Bio-Alcamid): a report of 18 cases J Plast Reconstr Aesthet Surg 59 1409 1414
25. ME Hillebrand SD Strackee BJG van Ulden JH ten Veen J van Dalen 2002 Behandeling van lipoatrofie in het gelaat met L-polymelkzuur: de PLA-studie Nederl Tijdschr Geneeskd 146 2274 2275
26. JE Ware Jr CD Sherbourne 1992 The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection Med Care 30 473 483
27. AW Wu HR Rubin WC Mathews JE Ware Jr LT Brysk WD Hardy SA Bozzette SA Spector DD Richman 1991 A health status questionnaire using 30 items from the Medical Outcomes Study. Preliminary validation in persons with early HIV infection Med Care 29 786 798
28. LS Radloff 1977 The Ces-D scale: a self-report depression scale for research in the general population Appl Psychol Measures 1 385 401
29. Y Ramon L Fodor Y Ullmann 2007 Preliminary experiences with Bio-Alcamid in HIV facial lipoatrophy Dermatosurgery 214 151 154
30. L Christensen V Breiting M Janssen J Vuust E Hogdall 2005 Adverse reactions to injectable soft tissue permanent fillers Aesthetic Plast Surg 29 34 48